Study title: J Nucl Med. 2003 Jan;44(1):24-9. Comment on: J Nucl Med. 2003 Jan;44(1):30-2. Impact of whole-body 18F-FDG PET on staging and managing patients for radiation therapy. Dizendorf EV, Baumert BG, von Schulthess GK, Lütolf UM, Steinert HC.
Type of medicine: Medicines containing chemical active substances | |||||
Therapeutic area: Neoplasms [C04] | |||||
Brands: Please see report | |||||
MAH holders: Please see report | |||||
Assessment: | |||||
Active substance: FLUDEOXYGLUCOSE | |||||
ATC code: | |||||
Document link: | |||||
Document date: | |||||
Study number: | |||||
EudraCT number: | |||||
Scope of study: Clinical | |||||
Population of study subjects: | Preterm newborn Infants | Newborn infants (1 to 27 days) | Infants and toddlers (28 days to 24 months) | Children (2 to 11 years) | Adolescents (12 to 18 years) |
- | - | - | Y | Y |